



HAL
open science

Regulation of drug transporter expression by oncostatin M in human hepatocytes

Marc Le Vee, Elodie Jouan, Bruno Stieger, Valérie Lecureur, Olivier Fardel

► To cite this version:

Marc Le Vee, Elodie Jouan, Bruno Stieger, Valérie Lecureur, Olivier Fardel. Regulation of drug transporter expression by oncostatin M in human hepatocytes. *Biochemical Pharmacology*, 2011, 82 (3), pp.304. 10.1016/j.bcp.2011.04.017 . hal-00711294

HAL Id: hal-00711294

<https://hal.science/hal-00711294>

Submitted on 23 Jun 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Regulation of drug transporter expression by oncostatin M in human hepatocytes

Authors: Marc LE VEE, Elodie JOUAN, Bruno STIEGER, Valérie LECUREUR, Olivier FARDEL



PII: S0006-2952(11)00290-5
DOI: doi:10.1016/j.bcp.2011.04.017
Reference: BCP 10889

To appear in: *BCP*

Received date: 27-3-2011
Revised date: 28-4-2011
Accepted date: 28-4-2011

Please cite this article as: VEE MLE, JOUANE, STIEGER B, LECUREUR V, FARDEL O, Regulation of drug transporter expression by oncostatin M in human hepatocytes, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2011.04.017

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1
2
3 Regulation of drug transporter expression by oncostatin M in human hepatocytes
4
5
6

7
8 Marc LE VEE^a, Elodie JOUAN^a, Bruno STIEGER^b, Valérie LECUREUR^a and Olivier
9 FARDEL^{a,c} *

10
11
12
13
14
15 ^aEA 4427 SeRAIC, Institut de Recherches Santé, Environnement et Travail, Université de
16
17 Rennes 1, 2 Avenue du Pr L. Bernard, 35043 Rennes, France

18
19
20 ^bDivision of Clinical Pharmacology and Toxicology, University Hospital, 8091, Zurich,
21
22 Switzerland

23
24
25 ^cDépartement HITC, Hôpital Pontchaillou, CHU, 2 rue Henri Le Guilloux, 35033 Rennes,
26
27 France

28
29
30
31
32
33
34 *Corresponding author. Tel: 33 (0)2 23 23 48 80; fax. : 33 (0)2 23 23 47 94.

35
36 E-mail address: olivier.fardel@univ-rennes1.fr
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ABSTRACT

1
2
3
4
5 The cytokine oncostatin M (OSM) is a member of the interleukin (IL)-6 family, known to
6
7 down-regulate expression of drug metabolizing cytochromes P-450 in human hepatocytes.
8
9
10 The present study was designed to determine whether OSM may also impair expression of
11
12 sinusoidal and canalicular drug transporters, which constitute important determinants of drug
13
14 hepatic clearance. Exposure of primary human hepatocytes to OSM down-regulated mRNA
15
16 levels of major sinusoidal solute carrier (SLC) influx transporters, including sodium-
17
18 taurocholate co-transporting polypeptide (NTCP), organic anion transporting polypeptide
19
20 (OATP) 1B1, OATP1B3, OATP2B1, organic cation transporter 1 and organic anion
21
22 transporter 2. OSM also repressed mRNA expressions of ATP binding cassette (ABC) efflux
23
24 transporters such as multidrug resistance protein (MRP) 2/ABCC2 and breast cancer
25
26 resistance protein/ABCG2, without however impairing those of multidrug resistance gene
27
28 1/P-glycoprotein/ABCB1, MRP3/ABCC3, MRP4/ABCC4 and bile salt export
29
30 pump/ABCB11. The cytokine concomitantly reduced NTCP, OATP1B1, OATP2B1 and
31
32 ABCG2 protein expression and NTCP and OATP transport activities. OSM effects towards
33
34 transporters were found to be dose-dependent and highly correlated with those of IL-6, but not
35
36 with those of other inflammatory cytokines such as tumor necrosis factor- α or interferon- γ . In
37
38 addition, OSM-mediated repression of some transporters such as NTCP, OATP1B1 and
39
40 OATP2B1, was counteracted by knocking-down expression of the type II OSM receptor
41
42 subunits through siRNA transfection. This OSM-mediated down-regulation of drug SLC
43
44 transporters and ABCG2 in human hepatocytes may contribute to alterations of
45
46 pharmacokinetics in patients suffering from diseases associated with increased production of
47
48 OSM.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. Introduction

Oncostatin M (OSM) is a member of the interleukin (IL)-6 family, secreted mainly by monocytes, macrophages, T cells and polymorphonuclear neutrophils [1, 2]. Numerous biological activities have been ascribed to OSM, including for example differentiation of megakaryocytes, inhibition of tumor cell growth, induction of neurotrophic peptides and bone remodeling [2]. In the liver, OSM has been involved in various physiological processes including development and regeneration [3, 4]; this has been hypothesized to occur through activation of the type II OSM receptor expressed by hepatocytes and formed by the association of glycoprotein 130 (gp130) and OSM receptor β (OSMR β) subunits [5, 6].

A well-recognized effect of OSM towards hepatocytes is the induction of acute-phase proteins such as C-reactive protein (CRP), thus supporting a role for OSM in liver inflammation [7, 8]. In addition, like other inflammatory cytokines such as IL-1 β , tumor necrosis factor (TNF)- α , IL-6 and interferon (IFN)- γ [9, 10], OSM has been shown to alter expression of drug metabolizing enzymes; OSM-treated human hepatocytes thus exhibit reduced expression and activity of various cytochromes P-450 (CYPs) such as CYP1A2, CYP2B6 and CYP3A4 [11]. By contrast, whether OSM may concomitantly alter expression of other hepatic detoxifying proteins such as drug transporters, which constitute major actors of the drug hepatobiliary secretion pathway [12, 13] and are well-established targets for inflammatory cytokines [14-17], remains unknown. The present study was therefore designed to gain insight about this point, through investigating the expression of main solute carrier (SLC) transporters, involved in drug uptake at the sinusoidal pole of hepatocytes, and ATP-binding cassette (ABC) transporters, usually acting as drug efflux pumps at the canalicular pole of hepatocytes, in OSM-treated primary human hepatocytes. Our data indicate that these

OSM-treated hepatocytes exhibit marked reduced expressions of SLC transporters and of some ABC transporters, with a global pattern of transporter changes close to that triggered by IL-6. These effects of OSM towards drug transporters, associated with known effects towards CYPs, may support the idea that up-regulation of OSM secretion in various physiological and pathological states may contribute to potential alteration of pharmacokinetics.

2. Materials and methods

2.1. Chemicals and reagents.

Recombinant human OSM was provided by R&D Systems (Minneapolis, MN). [³H(G)]taurocholic acid (sp. act. 1.19 Ci/mmol) and [6, 7-³H(N)]estrone-3-sulfate (sp. act. 57.3 Ci/mmol) were purchased from Perkin Elmer Life Sciences (Boston, MA). Probenecid was from Sigma-Aldrich (Saint-Quentin Fallavier, France). Antibodies against the ABC transporters P-glycoprotein/multidrug resistance gene 1/ABCB1 and breast cancer resistance protein/ABCG2 were provided by Alexis Biochemicals (Lausen, Switzerland), whereas those against multidrug resistance-associated protein (MRP)2/ABCC2 and MRP3/ABCC3 were from Chemicon International (Temecula, CA), and those directed against the mitogen-activated protein kinase (MAPK) phospho-extracellular signal regulated kinase (ERK) and total ERK from Cell Signaling Technology (Beverly, MA). All other compounds and reagents were commercial products of the highest purity available. Vehicle for OSM was phosphate-buffered saline; control cultures received the same dose of vehicle as treated counterparts.

2.2. Cell isolation and culture.

Human hepatocytes were obtained from adult donors undergoing hepatic resection for primary and secondary tumors, via the Biological Resource Center (Rennes, France). Cells

1 were prepared by perfusion of histologically-normal liver fragments using a collagenase
2 solution [18]. They were primary cultured on plastic dishes in Williams'E medium, as already
3 reported [19, 20]. All experimental procedures complied with French laws and regulations
4 and were approved by the National Ethics Committee.
5
6
7

8
9 Human highly-differentiated hepatoma HepaRG cells were routinely cultured in
10 Williams' E medium supplemented with 10% fetal calf serum, 100 IU/ml penicillin, 100
11 $\mu\text{g/ml}$ streptomycin, 5 $\mu\text{g/ml}$ insulin, 2 mM glutamine, and 5×10^{-5} M hydrocortisone
12 hemisuccinate; additional culture for two weeks in the same medium added with 2 %
13 dimethyl sulfoxide was performed in order to get a full hepatocytic differentiation of the cells
14 [21, 22].
15
16
17
18
19
20
21
22

23 24 25 26 27 *2.3. SiRNA transfection*

28 SiRNA transfection was performed in HepaRG cells as previously described [23]. Briefly,
29 HepaRG cells were trypsinized and replated in 24-multiwells with 100 nM chemically
30 synthesized, double-stranded, siRNAs targeting mRNAs of gp130 or OSMR β subunits,
31 provided by Sigma-Aldrich, or control non-targeting siRNAs (si-NT), provided by
32 Dharmacon (Lafayette, CO), in the presence of transfection medium, i.e. DharmaFECT-1
33 transfection reagent (Dharmacon) diluted in DMEM optimum/Williams'E medium
34 supplemented with 1% dimethyl sulfoxide. After 18 h, transfection medium was withdrawn
35 and cells were next maintained for 72 h in Williams'E medium described above, before being
36 treated with OSM.
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 52 53 *2.4. RNA isolation and analysis.*

54 Total RNA was isolated from cells using the TRIzol^R reagent (Invitrogen, Cergy-Pontoise,
55 France). RNA was then subjected to reverse transcription-real time quantitative polymerase
56
57
58
59
60
61
62
63
64
65

1 chain reaction (RT-qPCR) using the fluorescent dye SYBR Green methodology and an ABI
2 Prism 7300 detector (Applied Biosystem, Foster City, CA), as already reported [24]. Gene
3
4 primers for drug transporters and CRP were exactly as previously described [19]. Other
5
6 primers were MRP4/ABCC4 sense, GCTCAGGTTGCCTATGTGCT, ABCC4 antisense,
7
8 CGGTTACATTCCTCCTCCA, OSMR β sense, ATGCCATCATGACCTGGAA, OSMR β
9
10 antisense, CTCGCGCCATGTACTCTGT, gp130 sense, ATGAAGGTGGGAAGGATGG,
11
12 gp130 antisense, TGCCTTGGAGGAGTGAG. Relative quantification of the steady-state
13
14 target mRNA levels was calculated after normalization of the total amount of cDNA tested to
15
16 a 18S endogenous reference.
17
18
19
20
21
22
23

24 *2.5. Western-blot analysis.*

25
26 Total cellular or crude membrane extracts were prepared from primary human hepatocytes as
27
28 previously described [15]. Proteins were then separated on polyacrylamide gels and
29
30 electrophoretically transferred to nitrocellulose membranes. After blocking in Tris-buffered
31
32 saline containing 4 % bovine serum albumin, membranes were incubated overnight at 4°C
33
34 with primary antibodies directed against sodium-taurocholate cotransporting polypeptide
35
36 (NTCP)/SLC10A1, organic anion transporting polypeptide (OATP)2B1/SLCO2B1,
37
38 OATP1B1/SLCO1B1 [25], P-glycoprotein/ABCB1, ABCC2, ABCC3, ABCG2, phospho-
39
40 ERK or total ERK. Peroxidase-conjugated monoclonal antibodies were thereafter used as
41
42 secondary antibodies. After washing, immuno-labelled proteins were visualized by
43
44 chemiluminescence. Gel loading and transfer was checked up by staining membranes with
45
46 Ponceau red. The intensities of stained bands were measured by densitometry using ImageJ
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
1.40g software (National Institute of Health, Bethesda, MA).

58 *2.6. Transport assays.*

1 Transport activities due to NTCP or OATPs were analyzed through measuring sodium-
2 dependent-intracellular accumulation of the NTCP substrate taurocholate and probenecid-
3 sensitive uptake of the OATP substrate estrone-3-sulfate, as previously described [18].
4 Briefly, cells were incubated at 37°C for 10 min with 0.17 μM [^3H]taurocholate in the
5 presence or absence of sodium or with 1.7 nM [^3H]estrone-3-sulfate in the presence or
6 absence of the OATP inhibitor probenecid used at 2 mM. After washing in phosphate-
7 buffered saline, cells were lysed and accumulation of radiolabeled substrates was determined
8 through scintillation counting. Taurocholate accumulation values in the presence of sodium
9 minus accumulation values in the absence of sodium and estrone-3 sulfate uptake values in
10 the absence of probenecid minus uptake values in the presence of probenecid, are thought to
11 represent NTCP- and OATP-related transport activities [18].
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 *2.7. Statistical analysis.*

30
31 Quantitative data were usually expressed as means \pm SD. They were statistically analyzed
32 using the Student's *t* test, Kruskal-Wallis one-way analysis of variance followed by the
33 Student-Newman-Keuls test, or the nonparametric Spearman's rank correlation method. The
34 criterion of significance was $p < 0.05$. Data from dose-response studies were fitted using the
35 SigmaPlot software (Systat software, San Jose, CA).
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Results

3.1. Effects of OSM treatment on CRP expression.

Primary human hepatocytes from 6 liver donors were exposed to 10 ng/ml OSM for 8 h, 24 h or 48 h. This concentration of OSM was retained since it has been previously used for treating cultured hepatic cells in various studies [7, 26, 27]; it did not exert toxicity as demonstrated by phase-contrast microscopic examination of the cultures (data not shown). As shown in Table 1, OSM markedly increased mRNA expression of CRP, whatever the exposure time, even if the level of induction varied according to hepatocyte populations; such a variety in the level of induction has already been reported for regulation of referent inflammatory markers, including CRP, by cytokines in human hepatocytes [16]. Since CRP is a well-established target of OSM [7], these data indicated that primary human hepatocytes were fully responsive to OSM in our hands and were thus suitable for investigating OSM effects towards drug transporter expression.

3.2. Effects of OSM treatment on drug transporter mRNA expression.

We first analyzed the effects of OSM treatment on SLC transporter mRNA expression by RT-qPCR. As shown in Fig. 1A, human hepatocytes obtained from 6 individuals exhibited lower mRNA expression of OATP1B1, OATP1B3/SLCO1B3 and organic anion transporter 2 (OAT2)/ SLC22A7, when exposed to OSM, comparatively to untreated counterparts, whatever the time of treatment (8 h, 24 h or 48 h). With respect to OATP1B3 and OAT2, the time of exposure did not affect the level of expression repression in a major way, i.e. reduced levels of transporter expression found in hepatocytes exposed to OSM for 8 h, 24 h or 48 h were not statistically different; by contrast, OATP1B1 expression was found to statistically decrease with the time of exposure (Fig. 1A). OSM was also found to repress organic cation

1 transporter (OCT)1/SLC22A1, OATP2B1 and NTCP mRNA levels, but only in response to a
2 24-h or 48-h exposure (Fig. 1A).
3

4 We next studied the effects of OSM treatment on ABC transporter mRNA expression.
5
6 As shown in Fig. 1B, expression of ABCB1, bile salt export pump/ABCB11, ABCC3 and
7
8 ABCC4 remained statistically unchanged in hepatocytes exposed to OSM for 8 h, 24 h or 48
9
10 h, when compared to untreated counterparts. By contrast, OSM down-regulated ABCC2 and
11
12 ABCG2 expression, whatever the time of exposure; ABCG2 mRNA levels, unlike ABCG2
13
14 mRNA levels, were however lower in hepatocytes exposed to 24-h or 48-h to OSM when
15
16 compared to those found in counterparts exposed for only 8-h, suggesting a time-dependent
17
18 effect of the cytokine towards mRNA levels of this transporter.
19
20
21
22
23

24 When considering the repression factor after a 24-h exposure to OSM, i.e. the ratio of
25
26 mRNA levels in untreated hepatocytes versus those found in treated counterparts, NTCP was
27
28 the most repressed among the transporters affected by OSM, followed by OATP1B1,
29
30 ABCG2, OATP2B1, OATP1B3, OCT1, ABCC2 and OAT2 (Table 2). Interestingly, these
31
32 transporters, excepted OAT2 which has not been analysed, were also found to be repressed by
33
34 OSM in human highly differentiated hepatoma HepaRG cells (Table 2), known to represent a
35
36 useful alternative to primary human hepatocytes for investigating hepatic detoxifying
37
38 proteins, including transporters [22, 28]. A 8-h exposure to 10 ng/ml OSM moreover
39
40 markedly induced CRP mRNA expression by a 517.4 ± 264.0 -fold factor in HepaRG cells,
41
42 confirming that these hepatoma cells were fully responsive to OSM.
43
44
45
46
47

48 The dose-response relationship for OSM effects towards some transporters was next
49
50 characterized in primary human hepatocytes. As shown in Fig. 2, repressing effects of OSM
51
52 towards NTCP, OATP1B1, OATP1B3, OCT1, ABCC2 and ABCG2 were dose-dependent,
53
54 with EC50 ranging around 0.1 to 1 ng/ml. Treatment by 20 ng/ml OSM led to down-
55
56 regulations of transporter expression similar to those observed with 10 ng/ml OSM. The use
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

of OSM at 1 ng/ml also repressed transporters, but in a more moderate manner. The dose of 0.1 ng/ml was still partially active, except for ABCG2, whereas the lower concentration of 0.01 ng/ml has no obvious, or only very limited, effects on transporter mRNA expression (Fig. 2).

3.3. *Effects of OSM treatment on drug transporter protein expression.*

To determine whether some of the changes in transporter mRNA levels induced by OSM also occur at the protein level, we next performed Western-blot analysis of crude membranes from OSM-treated primary human hepatocytes and untreated counterparts. As indicated in Fig. 3, exposure to OSM for 48 h reduced expression of NTCP, OATP1B1, OATP2B1 and ABCG2. By contrast, it failed to obviously alter P-glycoprotein/ABCB1, ABCC2 and ABCC3 expression (Fig. 3).

3.4. *Effects of OSM treatment on transporter activities.*

Owing to the limited availability of human hepatocytes, we focussed on the effects of cytokine treatments on activities of NTCP and OATPs, whose mRNA expressions were among the most repressed by OSM (Table 2). As shown in Fig. 4, exposure to OSM for 48 h resulted in decreased NTCP and OATP transport activity in human primary hepatocytes, when compared to untreated counterparts.

3.5 *Correlation analysis of cytokine repressing effects on drug transporter mRNA expression in human hepatocytes.*

Besides OSM, various cytokines such as IL-1 β , TNF- α , IL-6 and IFN- γ , have been previously shown to down-regulate mRNA expression of various hepatic transporters [15, 16, 29]. In order to search for a putative correlation between these repressive effects of cytokines, drug

1 transporters were ranked according to the down-regulation of their mRNA expression in
2 response to a 24-h treatment by cytokines. Data used for OSM effects were from Fig. 1,
3
4 whereas those related to IL-1 β , TNF- α , IL-6 and IFN- γ effects have been previously obtained
5
6 using primary human hepatocytes cultured in the same conditions than those used in the
7
8 present study [15, 19, 29]. For each treatment, transporters were ranked from the most
9
10 repressed transporter to the less repressed according to mRNA expression levels. Correlations
11
12 were analyzed using the Spearman's rank correlation method. Results indicated that the
13
14 effects of OSM towards drug transporters were highly correlated with those of IL-6 and, in a
15
16 more moderate manner, with those of IL-1 β (Fig. 5). By contrast, they were not correlated
17
18 with those of TNF- α and IFN- γ (Fig. 5).
19
20
21
22
23
24
25
26

27 *3.6 Involvement of type II OSM receptor in OSM effects towards drug transporters.*

28
29 To investigate the implication of the type II OSM receptor in the repressing effects of OSM
30
31 towards drug transporters, we performed knock-down of its subunits OSMR β and gp130 in
32
33 HepaRG cells using siRNA transfection. As shown in Fig. 6A, HepaRG cells transfected with
34
35 siRNAs targeting OSMR β (si-OSMR β) or gp130 (si-gp130) exhibited reduced expressions of
36
37 OSMR β and gp130 mRNAs, which represent less than 25% of mRNA levels found in control
38
39 counterparts transfected with non-targeting siRNAs (si-NT). In order to determine whether
40
41 these type II OSM receptor subunit down-regulations have functional consequences, we
42
43 analyzed their implication towards OSM-mediated CRP mRNA induction. As indicated in
44
45 Fig. 6B, si-OSMR β - and si-gp130-transfected cells exposed to OSM exhibited reduced up-
46
47 regulation of CRP when compared to that occurring in control si-NT-transfected counterparts.
48
49 Moreover, they also displayed reduced levels of phospho-ERK, whereas total ERK expression
50
51 remained unchanged (Fig. 6C), knowing that the ERK pathway constitutes one of the major
52
53 signaling events activated by OSM, i.e. ERK is activated through phosphorylation in response
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

to OSM [30]. Taken together, these data strongly suggest that siRNA-mediated repression of type II OSM receptor subunits was functionally relevant in HepaRG cells, i.e. it resulted in decreased activity of OSM.

We next analyzed the consequences of siRNA-mediated OSMR β and gp130 subunit knockdown on OSM-mediated down-regulation of NTCP, OATP1B1 and OATP2B1, which are the three most repressed drug transporters in OSM-exposed HepaRG cells (Table 2). OSM-mediated repression of OATP1B1 and OATP2B1 was found to be counteracted in a major way by siRNA-mediated silencing of either OSMR β (Fig. 7A) or gp130 (Fig. 7B) subunits of type II OSM receptor. OSM-related repression of NTCP was also significantly attenuated (Fig. 7A and 7B).

4. Discussion

1
2
3
4
5 The data reported in the present study demonstrate that treatment by OSM can repress
6
7 expression of major drug transporters in human hepatocytes. SLC transporters are notably
8
9 affected in a major way, because OSM down-regulates mRNA levels of NTCP, involved in
10
11 sinusoidal uptake of bile acids, of OATP1B1, OATP1B3, OATP2B1 and OAT2, involved in
12
13 sinusoidal uptake of organic anions, and of OCT1, mediating sinusoidal uptake of organic
14
15 cations, in a dose-dependent manner. Moreover, some of these transporters such as NTCP,
16
17 OATP1B1 and OATP2B1 are also repressed at protein levels, and NTCP and OATP transport
18
19 activities are concomitantly reduced by OSM.
20
21
22
23

24 OSM also targets ABC efflux transporters, but in a more limited manner. Indeed, if
25
26 ABCG2 expression was repressed at both mRNA and protein level by OSM treatment in
27
28 primary human hepatocytes, other major ABC transporters such as P-glycoprotein/ABCB1,
29
30 ABCB11, ABCC3 and ABCC4 were not affected. With respect to the organic anion efflux
31
32 transporter ABCC2, its mRNA expression was down-regulated by OSM, whereas its protein
33
34 expression remained unaltered; the reason for such a discrepancy remains unclear, but it could
35
36 be linked to the relative low level of repression of ABCC2 mRNA expression by OSM in
37
38 primary human hepatocytes (by only a 1.8-fold-factor after a 24-h exposure to OSM; Table 2)
39
40 or could reflect divergent transcriptional and post-transcriptional effects of OSM towards
41
42 ABCC2 expression. Such differential effects of cytokines towards mRNA and protein
43
44 expressions of drug transporters have already been reported for the effects of IL-6 and TNF- α
45
46 towards some hepatic transporters. Indeed, IL-6 decreased ABCB1 mRNA levels in primary
47
48 human hepatocytes, without however affecting P-glycoprotein content, whereas TNF- α
49
50 increased protein expression of ABCG2 and ABCC3, without concomitant changes in mRNA
51
52 levels of these transporters [19].
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The mechanism by which OSM altered expression of transporters remains to be characterized. Type II OSM receptor, which has already been demonstrated to be implicated in hepatic effects of OSM [6], is most likely involved. Indeed, knock-down of gp130 and OSMR β subunits of this receptor counteracted down-regulation of NTCP, OATP2B1 and OATP1B1 mRNA expression by OSM in HepaRG cells. It can therefore be hypothesized that signaling pathways that are activated by this receptor, especially by its signal-transducing component gp130 subunit, may play a major role in OSM-related changes in transporter expression. The fact that these transporter expression alterations due to OSM treatment were highly correlated with those triggered by exposure to IL-6 fully supports this hypothesis, because IL-6 receptor also uses gp130 subunit for transduction pathway [31]. Through gp130 subunit, OSM and also IL-6, are known to activate several distinct signaling ways, including Janus kinase/signal transducer and activator of transcription cascade, MAPK pathway and phosphatidylinositol 3-kinase pathway [32]; in agreement with these data, the MAPK ERK was found to be activated by OSM in HepaRG cells (Fig. 6C). Analysis of the role that may play these different signaling pathways in OSM-related transporter repression would likely deserve further studies. In this context, it is however noteworthy that the effects of OSM towards transporter were not correlated with those of TNF- α or IFN- γ , suggesting that these cytokines mobilize independent signaling pathways for acting on transporters. With respect to the effects of IL-1 β on transporters, a correlation with those of OSM was observed; this likely indicate some partial interrelationships or crosstalks between IL-1 β -signaling pathways and those linked to OSM with respect to hepatic transporter regulation. The fact that at least MAPKs and STAT3 can be activated by both OSM and IL-1 β may support this hypothesis [15, 31, 33].

The putative physiological and pathological relevance of OSM effects towards human hepatic transporter expression remains to be precisely described. OSM exposure is however

likely to result in reduced sinusoidal uptake of drugs, owing to its global repressing effect toward influx SLC transporters. In addition, OSM-mediated down-regulation of ABCG2 expression may contribute to decreased biliary secretion of drugs such as the antibiotic nitrofurantoin handled by this canalicular ABC pump [34]. Associated with the known repression of drug metabolizing CYP activity triggered by OSM, these putative alterations of hepatic drug transport may contribute to alteration of pharmacokinetics. Such impairment of drug disposition may have notably to be considered in subjects exhibiting elevated circulating levels of OSM, such as preeclamptic pregnant women [35] or patients suffering from rheumatoid arthritis [36], systemic lupus erythematosus [37], periodontal diseases [38] or malignant hemopathies [39]. In this context, it is noteworthy that patients with these diseases may display serum OSM levels up to 1 ng/ml [35], which are therefore in the range of OSM concentrations exhibiting repressing activity on hepatic transporters *in vitro* (Fig. 2); this supports the idea that OSM serum levels up-regulated in some diseases may be sufficient to affect *in vivo* expression of drug transporters. Moreover, elevated hepatic expression of OSM has been reported in liver-injury conditions and cirrhosis [5, 40] and this *in situ* hepatic production of OSM, in association with the up-regulation of other hepatic inflammatory cytokines such as IL-1 β , TNF- α and IL-6, may therefore directly contribute to the decreased hepatobiliary secretion of drugs observed in these pathological situations [41]. In addition, the repressing effects of OSM towards NTCP expression and activity may lead to alteration of enterohepatic cycle of bile acids through impairment of their NTCP-mediated reuptake from blood at the sinusoidal pole of hepatocytes and, by this way, may contribute to cholestasis. Impairment of the biliary elimination of other endogeneous substrates for hepatic transporters, such as bilirubin handled by OATPs [42], may have also to be considered. Finally, it is noteworthy that OSM has been shown to impact brain endothelial cells and kidney tubular cells, which are well known to play a major role in drug disposition and elimination [30, 43,

1 44]; whether OSM may alter expression of drug transporters in these cells would likely
2 deserve further studies.
3

4 In conclusion, the current data demonstrate that OSM down-regulates expression of
5 drug transporters in human hepatocytes, especially that of sinusoidal uptake SLC transporters.
6
7 Such changes may likely contribute to alterations of pharmacokinetics in patients suffering
8
9 from diseases associated with increased production of OSM.
10
11
12
13
14
15
16

17 **Acknowledgements**

18 We would like to thank Dr. Michel Samson for helpful discussions and Dr. Laurent Vernhet
19
20 for critical reading of the manuscript.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Gomez-Lechon MJ, Oncostatin M: signal transduction and biological activity. *Life Sci* **65**(20): 2019-30, 1999.
2. Tanaka M and Miyajima A, Oncostatin M, a multifunctional cytokine. *Rev Physiol Biochem Pharmacol* **149**: 39-52, 2003.
3. Kamiya A, Gonzalez FJ and Nakauchi H, Identification and differentiation of hepatic stem cells during liver development. *Front Biosci* **11**: 1302-10, 2006.
4. Dierssen U, Beraza N, Lutz HH, Liedtke C, Ernst M, Wasmuth HE and Trautwein C, Molecular dissection of gp130-dependent pathways in hepatocytes during liver regeneration. *J Biol Chem* **283**(15): 9886-95, 2008.
5. Znoyko I, Sohara N, Spicer SS, Trojanowska M and Reuben A, Expression of oncostatin M and its receptors in normal and cirrhotic human liver. *J Hepatol* **43**(5): 893-900, 2005.
6. Nakamura K, Nonaka H, Saito H, Tanaka M and Miyajima A, Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. *Hepatology* **39**(3): 635-44, 2004.
7. Richards CD, Brown TJ, Shoyab M, Baumann H and Gauldie J, Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. *J Immunol* **148**(6): 1731-6, 1992.
8. Pardo-Saganta A, Latasa MU, Castillo J, Alvarez-Asiain L, Perugorria MJ, Sarobe P, Rodriguez-Ortigosa CM, Prieto J, Berasain C, Santamaria M and Avila MA, The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression. *J Hepatol* **51**(6): 1010-20, 2009.
9. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P and Guillouzo A, Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. *Mol Pharmacol* **44**(4): 707-15, 1993.
10. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R and Sinal CJ, Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. *Drug Metab Dispos* **36**(2): 205-16, 2008.
11. Guillen MI, Donato MT, Jover R, Castell JV, Fabra R, Trullenque R and Gomez-Lechon MJ, Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. *J Pharmacol Exp Ther* **285**(1): 127-34, 1998.
12. Chandra P and Brouwer KL, The complexities of hepatic drug transport: current knowledge and emerging concepts. *Pharm Res* **21**(5): 719-35, 2004.
13. Fardel O, Payen L, Courtois A, Vernhet L and Lecureur V, Regulation of biliary drug efflux pump expression by hormones and xenobiotics. *Toxicology* **167**(1): 37-46, 2001.
14. Petrovic V, Teng S and Piquette-Miller M, Regulation of drug transporters during infection and inflammation. *Mol Interv* **7**(2): 99-111, 2007.
15. Le Vee M, Gripon P, Stieger B and Fardel O, Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. *Drug Metab Dispos* **36**(2): 217-22, 2008.
16. Fardel O and Le Vee M, Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. *Expert Opin Drug Metab Toxicol* **5**(12): 1469-81, 2009.

17. Diao L, Li N, Brayman TG, Hotz KJ and Lai Y, Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF- α , IL-6, and IL-1 β . *J Biol Chem* **285**(41): 31185-92, 2010.
18. Jigorel E, Le Vee M, Boursier-Neyret C, Bertrand M and Fardel O, Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. *Drug Metab Dispos* **33**(10): 1418-22, 2005.
19. Le Vee M, Lecureur V, Stieger B and Fardel O, Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor- α or interleukin-6. *Drug Metab Dispos* **37**(3): 685-93, 2009.
20. Le Vee M, Lecureur V, Moreau A, Stieger B and Fardel O, Differential regulation of drug transporter expression by hepatocyte growth factor in primary human hepatocytes. *Drug Metab Dispos* **37**(11): 2228-35, 2009.
21. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C and Guguen-Guillouzo C, Infection of a human hepatoma cell line by hepatitis B virus. *Proc Natl Acad Sci U S A* **99**(24): 15655-60, 2002.
22. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F and Guguen-Guillouzo C, The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. *Chem Biol Interact* **168**(1): 66-73, 2007.
23. Le Vee M, Jouan E and Fardel O, Involvement of aryl hydrocarbon receptor in basal and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced expression of target genes in primary human hepatocytes. *Toxicol In Vitro* **24**(6): 1775-81, 2010.
24. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y and Fardel O, Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. *Drug Metab Dispos* **34**(10): 1756-63, 2006.
25. Huber RD, Gao B, Sidler Pfandler MA, Zhang-Fu W, Leuthold S, Hagenbuch B, Folkers G, Meier PJ and Stieger B, Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. *Am J Physiol Cell Physiol* **292**(2): C795-806, 2007.
26. Chung B, Verdier F, Matak P, Deschemin JC, Mayeux P and Vaulont S, Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone. *FASEB J* **24**(6): 2093-103, 2010.
27. Vollmer S, Kappler V, Kaczor J, Flugel D, Rolvering C, Kato N, Kietzmann T, Behrmann I and Haan C, Hypoxia-inducible factor 1 α is up-regulated by oncostatin M and participates in oncostatin M signaling. *Hepatology* **50**(1): 253-60, 2009.
28. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C and Fardel O, Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. *Eur J Pharm Sci* **28**(1-2): 109-17, 2006.
29. Le Vee M, Jouan E, Moreau A and Fardel O, Regulation of drug transporter mRNA expression by interferon-gamma in primary human hepatocytes. *Fundam Clin Pharmacol* **25**(1): 99-103, 2011.
30. Pollack V, Sarkozi R, Banki Z, Feifel E, Wehn S, Gstraunthaler G, Stoiber H, Mayer G, Montesano R, Strutz F and Schramek H, Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. *Am J Physiol Renal Physiol* **293**(5): F1714-26, 2007.
31. Silver JS and Hunter CA, gp130 at the nexus of inflammation, autoimmunity, and cancer. *J Leukoc Biol* **88**(6): 1145-56, 2010.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
32. Nakashima K and Taga T, gp130 and the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities. *Semin Hematol* **35**(3): 210-21, 1998.
 33. Yoshida Y, Kumar A, Koyama Y, Peng H, Arman A, Boch JA and Auron PE, Interleukin 1 activates STAT3/nuclear factor-kappaB cross-talk via a unique TRAF6- and p65-dependent mechanism. *J Biol Chem* **279**(3): 1768-76, 2004.
 34. Yue W, Abe K and Brouwer KL, Knocking down breast cancer resistance protein (ABCG2) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of ABCG2 to drug biliary excretion. *Mol Pharm* **6**(1): 134-43, 2009.
 35. Lee G, Kil G, Kwon J, Kim S, Yoo J and Shin J, Oncostatin M as a target biological molecule of preeclampsia. *J Obstet Gynaecol Res* **35**(5): 869-75, 2009.
 36. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH and Dickson MC, Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. *Arthritis Rheum* **58**(8): 2257-67, 2008.
 37. Robak E, Sysa-Jedrzejowska A, Stepien H and Robak T, Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. *Eur Cytokine Netw* **8**(3): 281-6, 1997.
 38. Pradeep AR, S TM, Garima G and Raju A, Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. *Biomarkers* **15**(3): 277-82, 2010.
 39. Koskela K, Pelliniemi TT, Remes K, Rajamaki A and Pulkki K, Serum oncostatin M in multiple myeloma: association with prognostic factors. *Br J Haematol* **96**(1): 158-60, 1997.
 40. Levy MT, Trojanowska M and Reuben A, Oncostatin M: a cytokine upregulated in human cirrhosis, increases collagen production by human hepatic stellate cells. *J Hepatol* **32**(2): 218-26, 2000.
 41. Verbeeck RK, Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. *Eur J Clin Pharmacol* **64**(12): 1147-61, 2008.
 42. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE and Schinkel AH, Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. *J Clin Invest* **120**(8): 2942-52, 2010.
 43. Takata F, Sumi N, Nishioku T, Harada E, Wakigawa T, Shuto H, Yamauchi A and Kataoka Y, Oncostatin M induces functional and structural impairment of blood-brain barriers comprised of rat brain capillary endothelial cells. *Neurosci Lett* **441**(2): 163-6, 2008.
 44. Luyckx VA, Cairo LV, Compston CA, Phan WL and Mueller TF, Oncostatin M pathway plays a major role in the renal acute phase response. *Am J Physiol Renal Physiol* **296**(4): F875-83, 2009.

Legends to figures

1
2
3
4
5 Fig. 1. Effects of OSM on drug transporter mRNA expression in human hepatocytes.

6
7 Primary human hepatocytes were either untreated or exposed to 10 ng/ml OSM for 8 h, 24 h
8
9 or 48 h. SLC (A) and ABC (B) transporter mRNA expression was then determined by RT-
10
11 qPCR, as described under Materials and Methods. Data are expressed for each transporter as
12
13 percentage of expression found in control untreated hepatocytes, arbitrarily set at the value of
14
15 100 %. They are the means \pm SD of values from six independent hepatocyte populations. *,
16
17 $p < 0.05$ when compared to untreated cells; #, $p < 0.05$ when compared to cells exposed to OSM
18
19 for 8 h; α , $p < 0.05$ when compared to cells exposed to OSM for 24 h (Student-Newman-Keuls
20
21 test).
22
23
24
25
26
27
28

29 Fig. 2. Dose-response of OSM effects towards drug transporter expression.

30
31 Primary human hepatocytes were either untreated or exposed to 0.01, 0.1, 1, 10 or 20 ng/ml
32
33 OSM for 48 h. Transporter mRNA expression was then determined by RT-qPCR, as
34
35 described under Materials and Methods. Data are expressed for each transporter as percentage
36
37 of expression found in control untreated hepatocytes, arbitrarily set at the value of 100 %, and
38
39 are the means \pm SD of values from four independent hepatocyte populations. They were fitted
40
41 with OSM concentrations, allowing to determine OSM EC50 for each transporter regulation.
42
43
44
45
46
47

48 Fig. 3. Effects of OSM on drug transporter protein expression in human hepatocytes.

49
50 Primary human hepatocytes were either untreated or exposed to 10 ng/ml OSM for 48 h.
51
52 Transporter protein content was then determined by Western-blot analysis. For each
53
54 transporter, data were quantified by densitometric analysis and expressed relatively to
55
56 transporter expression found in control untreated cells, arbitrarily set at the value of 100 %;
57
58
59
60
61
62
63
64
65

1 they are the means \pm SD of values from three (NTCP) or six (other transporters) independent
2 hepatocyte populations (upper panel). A representative blot is also shown for each transporter
3
4 (lower panel). *, $p < 0.05$ when compared to untreated cells (Student's *t* test).
5
6
7
8

9 Fig. 4. Effects of OSM on drug transporter activities in human hepatocytes.

10
11 Primary human hepatocytes were either untreated or exposed to 10 ng/ml OSM for 48 h.
12
13 NTCP and OATP activities were then determined using radiolabeled substrates as described
14
15 under Materials and Methods. Data are expressed relatively to transporter activity found in
16
17 control untreated cells, arbitrarily set at the value of 100 %; they are the means \pm SD of values
18
19 from five (NTCP activity) or six (OATP activity) independent hepatocyte populations. *,
20
21 $p < 0.05$ when compared to untreated cells (Student's *t* test).
22
23
24
25
26
27
28

29 Fig. 5. Rank correlation analysis of repressing effects of OSM, IL-6, TNF- α , IL-1 β and IFN- γ
30
31 towards drug transporter mRNA expression in human hepatocytes.

32
33 Drug transporters were ranked according to the down-regulation of their mRNA expression in
34
35 response to a 24-h treatment by OSM, IL-6, TNF- α , IL-1 β and IFN- γ , from data from Fig. 1
36
37 for OSM effects and from previous published data for the effects of the other cytokines
38
39 [15, 19, 29]. For this purpose, transporters were ranked for each treatment from the most
40
41 repressed transporter to the less repressed, through considering the repression factor for each
42
43 transporter, i.e. the ratio of mRNA levels in untreated hepatocytes versus those found in
44
45 treated counterparts. Correlations were analyzed using the Spearman's rank correlation
46
47 method. Spearman's rank coefficients (ρ) and *p* values are provided on the top of each
48
49 correlation graph.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 Fig. 6. Functional repression of OSMR β and gp130 subunits of the type II OSM receptor by
3
4 siRNA mediated transfection.
5

6
7 HepaRG cells were transfected with non-targeting siRNAs (si-NT) or with siRNAs targeting
8
9 OSMR β (si-OSMR β) or gp130 (si-gp130) as described under Materials and Methods. (A)
10
11 Expression of OSMR β and gp-130 mRNAs was then determined by RT-qPCR. Data are
12
13 expressed as percentage of expression found in control si-NT-transfected cells, arbitrarily set
14
15 at the value of 100 %, and are the means \pm SD of values from four independent experiments.
16
17
18
19 *, $p < 0.05$ when compared to si-NT-transfected cells (Student's t test). (B) Cells were exposed
20
21 to 10 ng/ml OSM for 24 h. CRP mRNA expression was then determined by RT-qPCR; data
22
23 are expressed as percentage of expression found in control OSM-untreated si-NT-transfected
24
25 cells, arbitrarily set at the value of 100 %, and are the means \pm SD of values from four
26
27 independent experiments. *, $p < 0.05$ when compared to OSM-treated si-NT-transfected cells
28
29 (Student-Newman-Keuls test). (C) Cells were exposed to 10 ng/ml OSM for 30 min.
30
31 Phospho-ERK and total ERK contents were next analyzed by Western-blot. Data shown are
32
33 representative of two independent experiments.
34
35
36
37
38
39
40
41

42 Fig. 7. Effects of OSMR β and gp130 subunit knock-down on OSM-mediated repression of
43
44 drug transporters.
45

46
47 HepaRG cells, transfected with non-targeting siRNAs (si-NT) or with siRNAs targeting
48
49 OSMR β (si-OSMR β) or gp130 (si-gp130) subunits of the type II OSM receptor, were
50
51 exposed to 10 ng/ml OSM for 24 h. Expression of the transporters NTCP, OATP1B1 and
52
53 OATP2B1 was then determined by RT-qPCR in si-OSMR β - (A) and si-gp130- (B)
54
55 transfected cells, as described under Materials and Methods; data are expressed as percentage
56
57 of expression found in control OSM-untreated si-NT-transfected cells, arbitrarily set at the
58
59
60
61
62
63
64
65

value of 100 %, and are the means \pm SD of values from five independent experiments. *,
p<0.05 when compared to OSM-treated si-NT transfected cells (Student's *t* test).

Accepted Manuscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1

Effects of OSM treatment on CRP mRNA expression in primary human hepatocytes

Exposure time to OSM	CRP mRNA expression (% of 18 S)	CRP mRNA fold-induction
0 h	0.0002 ± 0.0003	-
8 h	0.0141 ± 0.0102*	8453 ± 9934*
24 h	0.0567 ± 0.0373*	32011 ± 39266*
48 h	0.0260 ± 0.0171*	24695 ± 43352*

CRP mRNA fold-induction are defined as the ratio of CRP mRNA levels in OSM-treated primary hepatocytes versus those found in untreated counterparts.

Data are mean ± SD of values from six independent hepatocyte populations.

*, $p < 0.05$ when compared to untreated hepatocytes (Student-Newman-Keuls test).

Table 2

Repression of drug transporter expression in primary human hepatocytes and hepatoma HepaRG cells exposed to OSM

Transporter	Fold repression (mRNA levels)	
	Human hepatocytes	HepaRG cells
NTCP	9.8 ± 6.2	17.0 ± 2.9
OATP1B1	3.6 ± 1.2	4.6 ± 0.6
ABCG2	3.2 ± 1.6	3.1 ± 0.3
OATP2B1	2.6 ± 1.1	3.3 ± 0.6
OATP1B3	2.5 ± 1.1	2.3 ± 0.3
OCT1	2.4 ± 1.0	2.8 ± 1.0
ABCC2	1.8 ± 0.5	2.8 ± 0.4
OAT2	1.8 ± 0.7	Not Done

Fold repression are defined as the ratio of drug transporter mRNA levels in control untreated cells versus those found in counterparts exposed to 10 ng/ml OSM for 24 h.

Data are the mean ± SD of values from six independent populations (Human hepatocytes) or from three independent experiments (HepaRG cells).

Figure 1




Figure 1

Figure 2




Figure 2

Figure 3





Figure 3

Figure 4





Figure 4

Figure 5




Figure 5

Figure 6




Figure 6

Figure 7





Figure 7

